VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets will remain closed on 21st October 2019, due to Assembly Elections in Maharashtra.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1%
Mon, 20 Aug

VENUS REMEDIES has announced its results for the quarter ended June 2018. Here is a detailed performance review of the same:

VENUS REMEDIES Quarterly Financials

No. of Mths
Qtr. Ending
3
Jun-17*
3
Mar-18*
3
Jun-18*
QoQ ChangeYoY Change
Net SalesRs m782932655-29.7%-16.2%
Other incomeRs m132-52.1%27.0%
TurnoverRs m784935657-29.8%-16.2%
ExpensesRs m593838554-33.9%-6.6%
Gross profitRs m189941018.0%-46.5%
DepreciationRs m102628233.3%-19.4%
InterestRs m819877-21.8%-4.9%
Profit before taxRs m8-62-56-756.1%
TaxRs m0320-100.0%0.0%
Profit after taxRs m8-94-56-756.1%
Gross profit margin%24.210.115.5
Effective tax rate%0.0-50.90.0
Net profit margin%1.1-10.0-8.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter fell 16.2% on a year-on-year (YoY) basis. The expenses were down by 6.6% YoY during the same period.
  • The company's operating profit declined by 46.5% YoY during the quarter. Consequently, operating profit margins witnessed a decline and stood at 15.5% in 1QFY19 as against 24.2% in 1QFY18.
  • Depreciation charges and finance costs declined by 19.4% YoY and 4.9% YoY, respectively.
  • Other income increased by 27.0% YoY during the quarter.
  • Net profit for the quarter declined by 756.1% YoY. Net profit margins during the quarter declined from 1.1% in 1QFY18 to -8.5% in 1QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter fell 29.7% on a quarter-on-quarter (QoQ) basis. The expenses were down by 33.9% QoQ during the same period.
  • The company's operating profit increased by 8.0% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 15.5% in 1QFY19 as against 10.1% in 4QFY18.
  • Net profit for the quarter increased by 40.7% QoQ, while net profit margins increased from -10.1% in 4QFY18 to -8.5% in 1QFY19.

To see how VENUS REMEDIES has performed over the last eight quarters, please visit here.

VENUS REMEDIES Share Price Performance

Over the last one year, VENUS REMEDIES share price has moved up from Rs 91.7 to Rs 57.3, registering a Loss of Rs 34.4 or around 37.5%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 15,130.2 (up 0.8%). Over the last one year it has moved up from 12,938.2 to 15,130.2, a gain of 2,192 points (up 16.9%).

Overall, the S&P BSE SENSEX is up 20.4% over the year.

Current Valuations

At the current price of Rs 57.3, the price to book value (P/BV) ratio of VENUS REMEDIES stands at 0.1 times.

Equitymaster requests your view! Post a comment on "VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1%". Click here!

  

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Oct 18, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - ASTRAZENECA PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS